Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic hydrogel microparticle (microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic hydrogel microparticle (microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes. Using our proprietary biotechnology-derived protein therapy platform, iTOL-100, allogenic pancreatic islets are co-implanted and in preclinical studies have shown immune acceptance and long-term function of the graft with control of blood glucose levels and restoration of insulin secretion. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.
Development Pipeline
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Announces Formation of Scientific Advisory Board with Appointment of International Leaders in Immune Tolerance Discoveries
- Inaugural appointments include scientific founders of iTolerance's regenerative cell therapy pipeline with expertise across biomaterials, immune modulators, and pancreatic islet transplantation for Type 1 Diabetes- Company advances pioneering regenerative cell...
iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
Company advancing regenerative cell therapy platform technology with broad utility toward first-in-man study Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies Anthony Japour, M.D., a seasonedbiotech and pharmaceutical...
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Announces Formation of Scientific Advisory Board with Appointment of International Leaders in Immune Tolerance Discoveries
- Inaugural appointments include scientific founders of iTolerance's regenerative cell therapy pipeline with expertise across biomaterials, immune modulators, and pancreatic islet transplantation for Type 1 Diabetes- Company advances pioneering regenerative cell...
iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
Company advancing regenerative cell therapy platform technology with broad utility toward first-in-man study Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies Anthony Japour, M.D., a seasonedbiotech and pharmaceutical...